 |
 |
judith richards wrote: > EFNS CONGRESS: Cabergline Improves Nocturnal Parkinson’s Symptoms Just a reminder, for those who missed earlier postings: Cabergoline (Dostinex) got excellent reviews during its formal trials in PD subjects about 5 years ago, but prescription in the U.S. is approved only for hyperprolactinemia, a disorder of the pituitary gland. I understand that present producers, Pharmacia & Upjohn, haven't applied for its use as PD treatment for business reasons: Upjohn, the original developers of cabergoline, was bought out by Pharmacia, developers of the new dopamine agonist pramipexole (Mirapex), and managers of the new conglomerate evidently didn't want to compete with themselves. Maybe in the future, if Mirapex turns out to be less than the miracle drug expected, Dostinex for PD will get another shot. Cheers, Joe -- J. R. Bruman (818) 789-3694 3527 Cody Road Sherman Oaks, CA 91403-5013